The Portuguese government authorised an expenditure of 32.7 million euros ($35.9 million) for the purchase of medicines against Covid-19 in 2022, according to a government decree published.
The resolution of the Council of Ministers on Monday said the expenditure is necessary "because of the evolution of the pandemic situation," and aims to ensure the Portuguese people have access to "therapeutic options for the disease caused by the SARS-CoV-2 virus".
Signed by Portuguese Prime Minister Antonio Costa, the order authorises the acquisition of the antiviral drug Remdesivir, as well as funding for the storage and acquisition of vaccines against Covid-19, Xinhua news agency reported.
The Portuguese government said the expenditure is justified to "put an end to the pandemic" and provide "therapeutic alternatives to treat infected people", such as "monoclonal antibodies," "oral antivirals," and "immunomodulators".
Access to these medicines can only be granted through a centralised procurement procedure within the framework of the Strategy for Covid-19 Therapeutics program, whose management is the responsibility of the European Commission. (1 euro $1.10)
--IANS
int/khz/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU